1. Home
  2. GTEC vs GDTC Comparison

GTEC vs GDTC Comparison

Compare GTEC & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenland Technologies Holding Corporation

GTEC

Greenland Technologies Holding Corporation

HOLD

Current Price

$0.53

Market Cap

13.4M

Sector

Industrials

ML Signal

HOLD

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$1.15

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTEC
GDTC
Founded
2006
2018
Country
United States
Singapore
Employees
340
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
12.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GTEC
GDTC
Price
$0.53
$1.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
101.6K
14.4K
Earning Date
05-15-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.62
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.68
52 Week High
$2.26
$3.68

Technical Indicators

Market Signals
Indicator
GTEC
GDTC
Relative Strength Index (RSI) 34.30 64.38
Support Level $0.47 $0.93
Resistance Level $0.80 $1.25
Average True Range (ATR) 0.05 0.11
MACD -0.01 0.04
Stochastic Oscillator 34.79 72.18

Price Performance

Historical Comparison
GTEC
GDTC

About GTEC Greenland Technologies Holding Corporation

Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: